Emanuela Leone
Catanzaro, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications.
Journal: PloS one
Published: February 27, 2015
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
Journal: Journal of cellular physiology
Published: February 08, 2014
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.
Journal: Cell cycle (Georgetown, Tex.)
Published: October 05, 2013
In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma.
Journal: Oncotarget
Published: March 13, 2013
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 01, 2013
miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease.
Journal: Journal of cellular physiology
Published: November 30, 2012
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
Journal: Cell death & disease
Published: November 30, 2012
DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.
Journal: Oncotarget
Published: October 27, 2012
Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 05, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026